Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) is a clinical-stage biotechnology company pioneering bispecific antibody therapeutics for cancer treatment through its Biclonics® platform. This page provides investors and researchers with centralized access to official announcements, clinical trial updates, and strategic developments shaping the company's trajectory in immuno-oncology.
Find timely updates on Merus' investigational therapies, including progress across multiple cancer indications. Track key milestones such as regulatory feedback, partnership expansions with pharmaceutical collaborators, and financial performance updates. Our aggregation ensures efficient monitoring of material events without promotional bias.
Content spans clinical data disclosures, research collaborations with industry leaders like Incyte and Lilly, intellectual property developments, and financial reporting. Each update is categorized for quick scanning while maintaining technical accuracy required for biotech analysis.
Bookmark this page for streamlined access to Merus' evolving story in multispecific antibody development. Combine our news repository with SEC filings and scientific publications for comprehensive investment research approach.
Merus N.V. (Nasdaq: MRUS) reported its financial results for 2022, highlighting a net loss of $131.2 million, an increase from $66.8 million in 2021. Collaboration revenue decreased by $7.5 million to $41.6 million, primarily due to reduced revenue from partnerships with Lilly and Incyte. R&D expenses surged by $51.2 million to $149.4 million, driven by clinical services and personnel costs. The company maintains a strong cash position with $326.7 million in cash and equivalents, expected to fund operations into the second half of 2025. Key updates on clinical trials are anticipated in 2023 for Zenocutuzumab and Petosemtamab, indicating potential advancements in cancer treatment.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in several upcoming investor conferences. Lundberg's fireside chats are scheduled for:
- Guggenheim Healthcare Talks/Oncology Conference on February 8, 2023, from 11:20-11:45 a.m. ET
- SVB Securities Global Biopharma Conference on February 14, 2023, from 3:40-4:10 p.m. ET
- Citi's 2023 Oncology Leadership Summit on February 23, 2023, from 10:00-11:00 a.m. ET
Webcasts of these presentations will be available live on the company's Investors page, with archived versions accessible for a limited time post-event.
Merus N.V. (Nasdaq: MRUS) announces its 2023 outlook emphasizing progress in oncology treatments. The company has treated over 150 patients with NRG1+ cancer using zenocutuzumab (Zeno) monotherapy and aims for a BLA filing with the FDA. Upcoming clinical updates are expected for petosemtamab and MCLA-129 in 2023. Merus reported sufficient cash reserves to fund operations into the second half of 2025. Key collaborations with Incyte and Loxo Oncology continue to advance various bispecific antibody programs, showcasing Merus' commitment to innovative cancer treatments.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will speak at the Stifel 2022 Healthcare Conference on November 16, 2022, at 1:50 p.m. ET. The presentation will be available via webcast on the company's Investors page and archived for later viewing. Merus specializes in developing full-length multispecific antibodies, known as Biclonics® and Triclonics®, with potential applications in oncology.
Merus N.V. (MRUS) has provided a clinical and financial update for Q3 2022. Their lead program, MCLA-129, shows clinical activity with promising early efficacy data presented at the ENA Symposium. The FDA recommends further patient enrollment in the eNRGy trial for Zenocutuzumab (Zeno) to support a Biologics License Application (BLA) for NRG1+ cancers. Collaboration revenue decreased by $7.1 million year-over-year. Operating expenses increased, leading to a greater net loss of $24.6 million. As of September 30, 2022, Merus has $372.9 million in cash, sufficient to fund operations beyond 2024.
Merus N.V. (Nasdaq: MRUS) has reported interim clinical data for MCLA-129, a bispecific antibody targeting EGFR and c-MET. The phase 1/2 trial showed a favorable safety profile with no dose-limiting toxicities. Antitumor activity was noted in heavily pretreated patients across various tumor types, including confirmed partial responses. The initial recommended dose for phase 2 is set at 1500 mg biweekly. Key details will be discussed in an investor call on October 26. These findings highlight MCLA-129's potential efficacy as a treatment for advanced solid tumors, including non-small cell lung cancer (NSCLC).
Merus N.V. (MRUS) announced promising results from the phase 1/2 trial of MCLA-129, a bispecific antibody targeting EGFR and c-MET for advanced non-small cell lung cancer (NSCLC). The drug was well-tolerated, with no dose-limiting toxicities observed. Preliminary data showed anti-tumor activity in 13 evaluable patients, with two achieving partial responses. The recommended phase 2 dose is 1500 mg. Further data will be presented at the ENA Symposium on October 28, 2022, along with an investor call detailing the program update on October 26, 2022.
Merus N.V. (Nasdaq: MRUS) announced the selection of an abstract for a poster presentation at the 34th EORTC/NCI/AACR Symposium, scheduled for October 28, 2022. The poster will focus on MCLA-129, a bispecific antibody targeting EGFR and c-MET, currently in phase 1/2 study for advanced non-small cell lung cancer (NSCLC) and other solid tumors. Preclinical studies suggest MCLA-129 may effectively treat TKI-resistant NSCLC. The abstract will be available on October 12, 2022, and the poster can be accessed during the conference and on Merus' website.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology firm, announced that CEO Bill Lundberg will participate in a panel at Citi's 17th Annual BioPharma Conference on September 8, 2022, at 2:40 p.m. ET. This event highlights the company's innovative work in developing multispecific antibodies, including Biclonics® and Triclonics®. A live webcast will be available on the company’s investor page, and an archive of the presentation will be accessible for a limited time post-event.
For more details, visit Merus’ website and social media channels.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
